SCHEMBL904643

SCHEMBL904643

CC(C)(C)c1ccc2nc(-c3ccc(-c4ncccc4Cl)c4ccccc34)[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.58
FGFR1 P11362 2/20 0.55
FLT3 P36888 2/20 0.55
CLK4 Q9HAZ1 2/20 0.55
KDR P35968 2/20 0.55
PLK4 O00444 1/20 0.55
CHEK1 O14757 1/20 0.55
AURKA O14965 1/20 0.55
CHUK O15111 1/20 0.55
PDPK1 O15530 1/20 0.55
JAK2 O60674 1/20 0.55
ROCK2 O75116 1/20 0.55
MAP4K4 O95819 1/20 0.55
PAK4 O96013 1/20 0.55
CHEK2 O96017 1/20 0.55
ABL1 P00519 1/20 0.55
NTRK1 P04629 1/20 0.55
PRKCG P05129 1/20 0.55
INSR P06213 1/20 0.55
LCK P06239 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4185892 0.99 METAP2 (0.57) METAP2FGFR1FLT3CLK4KDR
SCHEMBL4174467 0.89 CBFB (0.58) METAP2DYRK1ATRPV1CBFB
SCHEMBL4188468 0.87 FGFR1 (0.55) METAP2FGFR1FLT3CLK4KDR
SCHEMBL4195665 0.86 TRPV1 (0.56) METAP2FGFR1FLT3CLK4KDR
SCHEMBL16471245 0.85 METAP2 (0.51) METAP2FGFR1FLT3CLK4KDR
SCHEMBL4184763 0.83 FGFR1 (0.51) METAP2FGFR1FLT3CLK4KDR
SCHEMBL4172367 0.83 TRPV1 (0.56) METAP2FGFR1FLT3CLK4KDR
SCHEMBL904637 0.83 TRPV1 (0.63) METAP2FGFR1FLT3CLK4KDR
SCHEMBL4188374 0.82 TRPV1 (0.62) METAP2FGFR1FLT3CLK4KDR
Hydrochloric Acid SCHEMBL4182587 0.82 TRPV1 (0.62) METAP2FGFR1FLT3CLK4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621915-B1 NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES DAE WOONG PHARMA (KR) 2016-04-20 EP claimed
US-9040572-B2 Method of preparing benzoimidazole derivatives DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-26 US claimed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP claimed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US claimed
EP-1861387-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2007-12-05 EP claimed
WO-2006080821-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2006-08-03 WO claimed
EP-2621915-B1 NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES DAE WOONG PHARMA (KR) 2016-04-20 EP disclosed
EP-2621915-B1 NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES DAE WOONG PHARMA (KR) 2016-04-20 EP disclosed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
US-9040572-B2 Method of preparing benzoimidazole derivatives DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-26 US disclosed
US-9040572-B2 Method of preparing benzoimidazole derivatives DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-26 US disclosed
EP-2621915-A2 NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES Daewoong Pharmaceutical Co., Ltd (KR) 2013-08-07 EP disclosed
WO-2012044043-A2 NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2012-04-05 WO disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
EP-1861387-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2007-12-05 EP disclosed
WO-2006080821-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same TRPV1, TRPA1, BDKRB2 METAP2 4226/4885FGFR1 667/4885FLT3 2318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.